Everzom
Description
We develop a therapeutic platform based on stem cell exosomes from adipose tissue with strong immunomodulatory and regenerative properties. We target 3 main therapeutic space : digestive tissu healing, dermatology and hepatology with targeting indications : crohn fistula and fibrostenosing wound, Hidradenitis suppurativa fistula, atopic dermatitis and acute liver failure.
We have very robust preclinical data in large animal and at 18 months from first in man. We have a strong GMP compliant manufacturing platform based on a patented technology and a formulation technology through thermosensitive hydrogel for enhanced efficacy for local delivery.